Dr. Jan Engels

Investment Manager

Following a bachelor’s degree in biotechnology, Dr. Jan F. Engels completed a PhD in chemistry and nanotechnology in Hong Kong, where he stayed the past 10 years. During his PhD studies he co-founded a medical device start-up in the field of ophthalmology and drug delivery with the position as VP technology. Next to R&D, his focus was on technology patents and business development with successful collaborations with listed companies in US, Europe, and Japan. Next to his start-up position, Jan has a part time lecturer position, teaching Entrepreneurship. After returning to Germany, he joined High-Tech Gründerfonds as an Investment Manager Life Science.

Portfolio

Posts & mentions

Press
18. November 2024

Sedivention raises €800,000 in pre-seed funding for novel obesity therapy 

The medtech start-up is developing a device for a one-time, minimally invasive therapy for obesity. Sedivention has secured €800,000 in funding from High-Tech Gründerfonds (HTGF). The fresh capital will be used to advance the first preclinical studies and product development. Munich, 18 November 2024 – The German medical technology start-up Sedivention has received €800,000 in pre-seed funding from HTGF, one of the leading and most active early-stage investors in German
 
Press
16. September 2024

Symphera Secures €2.4 Million in Seed Financing to revolutionize Laparoscopic Surgery

Munich-based MedTech startup Symphera, closes a successful seed financing round led by HTGF with participation from Bayern Kapital, CARMA FUND, UnternehmerTUM Funding for Innovators, Stern Stewart Ventures, IRCAD, and expert business angels. The company aims to streamline surgical procedures leading to greatly improved post-operative outcomes for patients. Symphera’s mission aligns perfectly with the growing trend in the healthcare sector aimed at making operating rooms more efficie
 
RAYDIAX_Founders
Press
26. October 2023

RAYDIAX secures €3.5 million in fresh capital to develop its therapy assistance computed tomography system in the fight against cancer

RAYDIAX, a Magdeburg spin-off of the STIMULATE research campus, secures a total of €3.5 million in seed funding and grants The capital will be used to advance the development of RAYDIAX’s assistance system for image-guided, minimally invasive cancer interventions up to the pre-clinical prototype and to accelerate market development in Europe and the US Investors in the seed round include High-Tech Gründerfonds (HTGF), bmp Ventures with the IBG funds and experienced business a
 
Press
12. July 2023

ReCatalyst Announces Successful Closing of Oversubscribed Seed Financing Round

ReCatalyst is developing a nano-tech platform for production of next-generation of intermetallic platinum-alloy PEM fuel cell catalysts with the core mission to enable an optimized usage of platinum group metals.   Slovenian Startup ReCatalyst was able to convince an outstanding international syndicate consisting of HTGF, xista science ventures and OCCIDENT, along with Slovenian investors, to invest €1.7 million. The funding will be used to enhance market readiness and accele
 
Press
23. March 2023

Microbiome therapeutics biotech mbiomics raises EUR 13 million in first closing of Series A round

Munich, Germany, 23 March 2023 – mbiomics GmbH, a pioneering microbiome biotech company developing the first generation of effective microbiome-based therapeutics announced today the first closing of EUR 13 million (US$ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors. mbiomics uses its proprietary, tailored high-resolution profiling platform and computat